logo-loader
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals chief hails a year of significant progress

Boss, Dr Vladislav Sandler, said the company is making progress towards submitting an investigational new drug application

blood in testubes
The drug developer is a specialist in blood borne diseases

HemoGenyx Pharmaceuticals PLC (LON:HEMO) chief executive Dr Vladislav Sandler described 2017 as a “significant year” after the company listed on the market and inked a collaboration with Oxford University.

But perhaps the most exciting development occurred after the period-end as the company was able to show that its CDX antibodies can attack and eliminate acute myelogenous leukaemia.

While the data emanated from a pre-clinical study, it was nevertheless encouraging.

In Monday's full-year results statement, shareholders were told work is “progressing successfully” towards  the goal of submitting an investigational new drug application to the US Food and Drug Administration for its CDX antibodies product.

Lake Pharma deal

During the 12 months ended December 31, the company appointed Lake Pharma supplier of CDX antibodies, while the tie-up with Oxford University will help accelerate development of Hemogenyx's blood cancer treatments.

"2017 was a significant year for Hemogenyx as we successfully listed the business on the London Stock Exchange and raised the financing necessary to further develop novel therapies with the potential to transform the lives of bone marrow transplant patients,” said CEO Sandler.

“We remain on track in the development of both of our products according the timescale we outlined to investors in October. We continue to successfully develop our Hu-PHEC cell therapy product and we are on course to have our CDX antibodies product in readiness for the start of phase I trials as planned.”

In common with companies at this formative stage of development Hemogenyx was loss-making. The deficit was £2.32mln. The company was sitting on just under £1.9mln of cash at the period-end.

Quick facts: HemoGenyx Pharmaceuticals

Price: 8.04 GBX

LSE:HEMO
Market: LSE
Market Cap: £34.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read